MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report issued on Thursday. The brokerage issued a buy rating on the stock.

A number of other research analysts have also recently issued reports on MEIP. TheStreet cut MEI Pharma from a c- rating to a d+ rating in a report on Thursday, February 1st. Stifel Nicolaus reissued a hold rating and set a $7.00 price objective on shares of MEI Pharma in a report on Friday, April 12th.

MEI Pharma Stock Down 0.9 %

MEI Pharma stock opened at $3.16 on Thursday. The stock has a 50-day simple moving average of $3.42 and a 200 day simple moving average of $4.75. MEI Pharma has a 12-month low of $2.87 and a 12-month high of $7.87. The stock has a market capitalization of $21.05 million, a price-to-earnings ratio of 0.81 and a beta of 0.82.

Institutional Trading of MEI Pharma

An institutional investor recently bought a new position in MEI Pharma stock. National Bank of Canada FI bought a new position in shares of MEI Pharma, Inc. (NASDAQ:MEIP) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned 0.09% of MEI Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 52.38% of the company’s stock.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.